Constipation
Conditions
Interventions
Administration of BIOFERMIN tablets
Sponsors
Maruyama Michio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The elderly over 65 years old. Patients who cannot defecate by themselves,requiring defecation assistance. Patients who can take nutrition and drugs orally or by tube at the time of enrollment. Patients who have less than 3 spontaneous bowel movements per week during the pre-observation period. Patients who receive defecation treatment or additional laxatives at least once a week during the pre-observation period. Patients who can provide the written consent for participation in this study. However,if the consent cannot be obtained by the patient,it is possible to obtain consent from a legally acceptable representative.
Exclusion criteria
Exclusion criteria: Patients who have been pointed out to have organic abnormalities in the digestive tract. Patients with serious complications. Patients with infectious diseases. Patients with active malignant tumors. Patients who are allergic to intestinal medicine. Patients who took probiotic products within two weeks before enrollment. Patients who took opioid analgesics within two weeks before enrollment. Patients who have been using psychiatric drugs for the treatment of psychiatric disorders, except for the use of sleeping pills or psychotropic drugs as needed. Patients who took antibacterial agents within two weeks before enrollment. Patients who started the new drug administration within two weeks before enrollment. Patients who are inadequate to be enrolled in the study judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the number of spontaneous bowel movements before and six weeks after starting the treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in fecal properties over time at each evaluation point. Changes of the total number of defecations over time at each evaluation point. Changes of the number of spontaneous bowel movements over time before starting the administration, at six weeks and 8 weeks after starting the treatment. Changes of the number of uses of additional laxatives over time at each evaluation point. Changes of the number of defecation treatments(suppositories, enemas, disimpaction)over time each evaluation point. Changes of defecation days over time at each evaluation point. Changes in intestinal flora over time at each evaluation point. Changes in organic acids in feces over time at each evaluation point. Changes in vital signs over time at each evaluation point. Changes in frequency of fever over time at each evaluation point. | — |
Contacts
Public ContactMichio Maruyama
Ryokushukai Medical corporation, Tanashi hospital and care aid medical center
Outcome results
None listed